Mepolizumab is under clinical development by GSK and currently in Phase III for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase III drugs for Chronic Obstructive Pulmonary ...

This is a multi-center, randomized, placebo-controlled, double-blind, parallel group trial evaluating mepolizumab 100 mg against placebo given every 4 weeks through subcutaneous (SC) injection. In ...

Mepolizumab is already approved in China as an add-on maintenance treatment for adults and adolescents aged 12 years and older with severe eosinophilic asthma as well as for adults with ...

GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Although their specific mechanisms of action differ, there is as yet no guidance on whether to choose mepolizumab or benralizumab for any given patient. Aims To investigate clinical outcomes of ...

The study met its primary endpoint with the addition of mepolizumab to inhaled maintenance therapy, achieving a “statistically significant and clinically meaningful reduction” in the ...

Introduction Mepolizumab (anti-IL-5) and omalizumab (anti-IgE) are the only biologics licensed for asthma in children from age 6. Omalizumab is of known effectiveness, but mepolizumab lacks paediatric ...

1 The Phase III MIRRA study demonstrated that patients with EGPA spent more time in remission and had reduced oral corticosteroid (OCS) use with mepolizumab versus placebo. 2 Objectives To evaluate ...

2 3 However, its efficacy on respiratory manifestations seems limited. Conversely, the anti-IL5 mepolizumab, recently licensed for relapsing-refractory EGPA, is effective on respiratory manifestations ...

Currently there are four NICE approved biologics for severe asthma (Omalizumab, Mepolizumab, Reslizumab and Benralizumab). Omalizumab is indicated for severe allergic asthma and the other three ...